STOCK TITAN

Azenta approves plan to close 3 labs, cut workforce

Azenta estimates approximately $11.0 million in annualized savings after implementation, alongside pre-tax charges of approximately $11.0 million to $13.0 million.

(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Azenta, Inc. (AZTA) approved and committed to a restructuring plan on October 5, 2026, covering its Multiomics segment. The plan includes workforce reductions and the closure of three North American Multiomics laboratory sites; Azenta began notifying affected employees on October 6, 2026. The company says the plan is intended to consolidate its laboratory network, simplify its organization and improve operating efficiency.

Azenta estimates aggregate pre-tax charges of approximately $11.0 million to $13.0 million, consisting primarily of approximately $9.0 million in asset impairment charges and approximately $3.0 million in employee severance and other restructuring charges. Estimated future cash expenditures are approximately $7.0 million. The company expects substantially all charges in the fiscal year ending September 30, 2027, and expects to substantially complete the actions by March 31, 2027, subject to applicable legal and employee notice and consultation requirements. It expects approximately $11.0 million in annualized cost savings once fully implemented. Actual charges, timing and savings may differ from estimates due to implementation matters.

Positive

  • Minor point. Forward-looking: it has not happened yet and may not happen.Expected annualized savings of approximately $11.0 million once fully implemented.

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.Azenta expects a $9.0 million impairment charge on facilities it plans to exit.

Insights

Analyzing...

Item 2.05 Costs Associated with Exit or Disposal Activities Financial
The company committed to an exit plan involving layoffs, facility closures, or restructuring charges.
Item 2.06 Material Impairments Financial
The company concluded that a material charge for impairment of assets (goodwill, intangibles, etc.) is required.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Estimated aggregate pre-tax charges Approximately $11.0 million to $13.0 million Restructuring plan
Estimated impairment charge Approximately $9.0 million Long-lived assets associated with facilities expected to be exited
Employee severance and other restructuring charges Approximately $3.0 million Restructuring plan
Estimated future cash expenditures Approximately $7.0 million Restructuring plan
Expected annualized cost savings Approximately $11.0 million Once the plan is fully implemented
Multiomics laboratory sites planned for closure 3 sites North America
pre-tax charges financial
"aggregate pre-tax charges of approximately $11.0 million to $13.0 million"
Pre-tax charges are expenses a company records on its income statement before calculating income taxes; they reduce pretax profit and include items like write-downs, restructuring costs, impairments, or large legal settlements. They matter to investors because they can sharply change reported earnings in a single period, so looking past one-time or non-operational pre-tax charges helps compare underlying business performance, similar to spotting a one-off bill that temporarily cuts into a household’s monthly income.
annualized cost savings financial
"approximately $11.0 million of annualized cost savings"
right-of-use asset technical
"operating lease right-of-use asset"
A right-of-use asset is the value a company records on its balance sheet for the practical use of something it leases — like the benefit of living in a rented office or using leased equipment for a set period. Investors care because it turns many leases into on-balance-sheet assets and matching liabilities, which can change reported leverage, asset base and performance metrics much like taking on a loan would.
leasehold improvements technical
"related leasehold improvements associated with the leased facilities"
Leasehold improvements are changes a tenant makes to rented property—like adding walls, lighting, or specialized equipment—to suit its business, similar to renovating an apartment to fit your needs. Investors care because these improvements are recorded as long-term assets that are paid for upfront but written off over time, affecting reported profits, tax payments, cash flow and the value of a company’s assets on the balance sheet.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What charges does AZTA expect from the restructuring?

Azenta estimates aggregate pre-tax charges of approximately $11.0 million to $13.0 million. The estimate consists primarily of approximately $9.0 million in asset impairment charges and approximately $3.0 million in employee severance and other restructuring charges.

How many labs is AZTA closing?

Azenta's plan includes the closure of three Multiomics laboratory sites in North America and workforce reductions. The company began notifying affected employees on October 6, 2026.

When does AZTA expect to complete the restructuring?

Azenta expects to substantially complete the plan's actions by March 31, 2027, subject to applicable legal and employee notice and consultation requirements. It expects to recognize substantially all charges during the fiscal year ending September 30, 2027.

What are the expected annual savings for AZTA?

Azenta expects approximately $11.0 million of annualized cost savings once the plan is fully implemented.

What does AZTA's impairment charge relate to?

The approximately $9.0 million impairment charge consists primarily of operating lease right-of-use assets and related leasehold improvements associated with leased facilities Azenta expects to exit before the lease terms expire.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
0000933974FALSE00009339742026-10-052026-10-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 5, 2026
Azenta, Inc.
(Exact name of registrant as specified in its charter)
Delaware0-2543404-3040660
(State or Other Jurisdiction
of Incorporation)
(Commission File
Number)
(IRS Employer
Identification No.)
200 Summit Drive, Burlington, MA 01803
(Address of principal executive offices and Zip Code)
(888) 229-3682
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par valueAZTAThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o



Item 2.05. Costs Associated with Exit or Disposal Activities.

On October 5, 2026, the Board of Directors of Azenta, Inc. (the “Company”) approved, and the Company committed to, a restructuring plan (the “Plan”) within the Company’s Multiomics reportable segment. The Plan is intended primarily to consolidate the Company’s North American laboratory network, simplify its organizational structure and improve operating efficiency, and consists of workforce reductions and the closure of three of the Company’s Multiomics laboratory sites in North America. The Company began notifying affected employees of the actions contemplated by the Plan on October 6, 2026.

The Company currently estimates that it will incur aggregate pre-tax charges of approximately $11.0 million to $13.0 million in connection with the Plan, consisting primarily of approximately $9.0 million of asset impairment charges described under Item 2.06 below and approximately $3.0 million of employee severance and other restructuring charges. The Company currently estimates that the aggregate future cash expenditures associated with these charges will be approximately $7.0 million.

The Company expects to recognize substantially all of the charges during the fiscal year ending September 30, 2027, and to substantially complete the actions contemplated by the Plan by March 31, 2027, subject to applicable legal and employee notice and consultation requirements. The Company expects the Plan to generate approximately $11.0 million of annualized cost savings once fully implemented.

The Plan is separate from, and in addition to, restructuring actions that the Company initiated and completed earlier in its fiscal year ending September 30, 2026, consisting of actions within its Sample Management Solutions reportable segment in August 2026 and actions within its Multiomics reportable segment in September 2026. Those earlier actions did not result in material charges, individually or in the aggregate, and the associated charges are reflected in the Company’s results for the periods in which they were incurred.

The Company may identify additional actions under the Plan as implementation proceeds and continues to evaluate other opportunities to improve its operating efficiency and cost structure. Any such additional actions would be subject to applicable internal approvals, and the Company will provide information regarding them as and when required.

The estimates set forth above reflect the Company’s current expectations. Actual charges, timing and savings may differ from these estimates due to changes in the scope or timing of the actions, negotiations with landlords, applicable legal requirements and other implementation matters.

Item 2.06. Material Impairments.

In connection with, and as part of, the Plan described under Item 2.05 above, on October 5, 2026 the Company concluded that it will be required to record a material charge for impairment of long-lived assets, consisting primarily of the operating lease right-of-use asset and related leasehold improvements associated with the leased facilities that the Company expects to exit prior to the expiration of the lease terms. The Company currently estimates that this impairment charge will be approximately $9.0 million, which is included within the estimated aggregate pre-tax charges disclosed under Item 2.05 above.

Cautionary Note Regarding Forward-Looking Statements. This Current Report on Form 8-K contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the Plan, the actions contemplated by the Plan and the expected timing and completion of those actions, the estimated charges and cash expenditures the Company expects to incur in connection with the Plan, the estimated impairment charge, the annualized cost savings the Company expects the Plan to generate, and the possibility of additional actions under the Plan or otherwise. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including the Company’s ability to implement the Plan on the anticipated timetable and to realize the anticipated benefits and cost savings, the outcome of negotiations with landlords and other third parties, applicable legal and employee notice and consultation requirements, the Company’s ability to retain and attract key personnel, potential disruption to the Company’s operations and customer relationships during implementation, and the other factors described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Although the Company’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made herein speaks only as of the date on which it is made. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether because of new information, future developments or otherwise.







Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
EXHIBIT
NUMBER
DESCRIPTION
104Cover Page Interactive Data File (embedded within Inline XBRL document).





SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AZENTA, INC.
/s/ Ephraim Starr
Date: October 7, 2026Ephraim Starr
Senior Vice President, General Counsel and Secretary

Filing Exhibits & Attachments

3 documents

Keep reading